J&J Faces New Round Of Risperdal Suits With Ghostwriting Claims
Executive Summary
Johnson & Johnson has been hit with another wave of Risperdal (risperidone) product liability suits. While previous suits have claimed the antipsychotic caused diabetes, the current batch alleges that the drug induced gynecomastia, or breast enlargement, in boys and young men
You may also be interested in...
The New Ghostbuster: Elsevier Reviews Articles On Wyeth Drugs
Elsevier's investigation follows reports that Wyeth hired an outside company to write positive articles about its drugs; publisher also responds to Sen. Grassley letter.
Merck Accepts DTC Limits In Deal With States
Firm to pay $58 million to settle claims its consumer ads deceived the public on Vioxx safety.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011